KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Operations (2020 - 2025)

Aurinia Pharmaceuticals' Cash from Operations history spans 6 years, with the latest figure at 45668000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 51.65% year-over-year to 45668000.0; the TTM value through Dec 2025 reached 135658000.0, up 205.62%, while the annual FY2025 figure was 135658000.0, 205.62% up from the prior year.
  • Cash from Operations reached 45668000.0 in Q4 2025 per AUPH's latest filing, up from 44449000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 45668000.0 in Q4 2025 to a low of 53541000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 4531800.0, with a median of 8051500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 136.82% in 2021, then surged 660.62% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 25922000.0 in 2021, then skyrocketed by 140.31% to 10450000.0 in 2022, then surged by 36.96% to 14312000.0 in 2023, then skyrocketed by 110.41% to 30114000.0 in 2024, then soared by 51.65% to 45668000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Cash from Operations are 45668000.0 (Q4 2025), 44449000.0 (Q3 2025), and 44241000.0 (Q2 2025).